Trial Search Results
Oxytocin Infusions and Blood Loss in Patients Undergoing Elective Cesarean Delivery.
Although prior dose-finding studies have investigated the optimal bolus dose of oxytocin to initiate adequate uterine tone, it is unclear what oxytocin infusion regimen is required to maintain adequate uterine tone after delivery. The study investigators aim to compare two different infusion rates of oxytocin to assess the optimal infusion regimen for reducing blood loss in women undergoing elective Cesarean delivery.
Stanford is currently not accepting patients for this trial.
- Drug: Oxytocin Infusion
- Healthy pregnant patients with uncomplicated pregnancies:
- ASA (American Association of Anesthesiologists) class 1 or 2 patients.
- Singleton pregnancies.
- ASA class 3 or 4 patients.
- Known drug allergy to intravenous oxytocin.
- Significant medical or obstetric disease.
- Known uterine abnormality.
- Known placental abnormality.
Ages Eligible for Study
18 Years - 40 Years
Genders Eligible for Study